UA81628C2 - Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози - Google Patents

Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози

Info

Publication number
UA81628C2
UA81628C2 UA20041210381A UA20041210381A UA81628C2 UA 81628 C2 UA81628 C2 UA 81628C2 UA 20041210381 A UA20041210381 A UA 20041210381A UA 20041210381 A UA20041210381 A UA 20041210381A UA 81628 C2 UA81628 C2 UA 81628C2
Authority
UA
Ukraine
Prior art keywords
cyclophosphamide
doxorubicin
ovarian cancer
breast
docetaxel
Prior art date
Application number
UA20041210381A
Other languages
English (en)
Russian (ru)
Inventor
Ішем Шакрун
Original Assignee
Авентіс Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентіс Фарма С.А. filed Critical Авентіс Фарма С.А.
Publication of UA81628C2 publication Critical patent/UA81628C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Даний винахід стосується застосування доцетакселу у комбінації з доксорубіцином і циклофосфамідом як лікарського препарату допоміжної терапії при лікуванні метастатичного раку молочної залози у хворих з надекспресованими залозами ER, PR і або HER2, що забезпечує підвищений коефіцієнт виживаності.
UA20041210381A 2002-05-17 2003-05-15 Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози UA81628C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38085002P 2002-05-17 2002-05-17
PCT/EP2003/007443 WO2003097164A1 (en) 2002-05-17 2003-05-15 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer

Publications (1)

Publication Number Publication Date
UA81628C2 true UA81628C2 (uk) 2008-01-25

Family

ID=29550025

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210381A UA81628C2 (uk) 2002-05-17 2003-05-15 Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози

Country Status (28)

Country Link
US (2) US20040014694A1 (uk)
EP (1) EP1507573A1 (uk)
JP (1) JP4773719B2 (uk)
KR (1) KR20050000544A (uk)
CN (1) CN1652845A (uk)
AU (1) AU2003244646B2 (uk)
BR (1) BR0310026A (uk)
CA (1) CA2486124A1 (uk)
CR (1) CR7575A (uk)
EC (1) ECSP045433A (uk)
HR (1) HRPK20041072B3 (uk)
IL (1) IL165214A0 (uk)
MA (1) MA27417A1 (uk)
ME (2) MEP16308A (uk)
MX (1) MXPA04010640A (uk)
MY (1) MY146533A (uk)
NO (1) NO20045370L (uk)
NZ (1) NZ535992A (uk)
OA (1) OA12819A (uk)
PA (1) PA8574001A1 (uk)
RS (1) RS96304A (uk)
RU (1) RU2321396C2 (uk)
TN (1) TNSN04217A1 (uk)
TW (1) TWI374741B (uk)
UA (1) UA81628C2 (uk)
UY (1) UY27812A1 (uk)
WO (1) WO2003097164A1 (uk)
ZA (1) ZA200408549B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2008027988A2 (en) * 2006-08-31 2008-03-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
JP6309454B2 (ja) 2011-11-30 2018-04-11 アストラゼネカ アクチボラグ 癌の併用処置
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
EP3581586A1 (en) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
EP3366296B1 (en) * 2015-10-22 2020-01-15 Universidade De Santiago De Compostela Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash)
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2018039452A1 (en) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods of treating cancers with chemotherapy with reduced toxicity
WO2018067575A1 (en) * 2016-10-03 2018-04-12 Indiana University Research And Technology Corporation Combination drug therapy reduces parp-1 related dna repair and increases the efficacy of genotoxic agents
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
CN116850283A (zh) 2017-03-02 2023-10-10 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
KR20210048483A (ko) * 2018-06-22 2021-05-03 오하이오 스테이트 이노베이션 파운데이션 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
KR20050000544A (ko) 2005-01-05
CN1652845A (zh) 2005-08-10
CR7575A (es) 2006-05-10
RU2321396C2 (ru) 2008-04-10
MXPA04010640A (es) 2005-08-16
CA2486124A1 (en) 2003-11-27
WO2003097164A1 (en) 2003-11-27
RS96304A (en) 2006-10-27
ME00055B (me) 2010-10-10
PA8574001A1 (es) 2003-12-19
MY146533A (en) 2012-08-15
UY27812A1 (es) 2003-11-28
MA27417A1 (fr) 2005-07-01
MEP16308A (en) 2010-06-10
JP4773719B2 (ja) 2011-09-14
AU2003244646B2 (en) 2008-08-07
IL165214A0 (en) 2005-12-18
EP1507573A1 (en) 2005-02-23
US20070265213A1 (en) 2007-11-15
TW200407152A (en) 2004-05-16
TWI374741B (en) 2012-10-21
NZ535992A (en) 2008-11-28
TNSN04217A1 (en) 2007-03-12
RU2004136984A (ru) 2005-06-27
JP2005529925A (ja) 2005-10-06
US20040014694A1 (en) 2004-01-22
OA12819A (en) 2006-07-10
ECSP045433A (es) 2005-01-03
HRPK20041072B3 (en) 2007-07-31
BR0310026A (pt) 2005-02-15
HRP20041072A2 (en) 2005-06-30
NO20045370L (no) 2004-12-08
ZA200408549B (en) 2006-01-25
AU2003244646A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
BRPI0518250A2 (pt) tratamentos anticÂncer
IL155781A0 (en) Effective antitumor treatments
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
HK1068606A1 (en) Novel aminobenzoephenones
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
IL159770A0 (en) Calcium salts with cytotoxic activity
AU2003229876A8 (en) Tumour associated antigens
MXPA05011568A (es) Uso de irinotecan para el tratamiento de cancer recurrente de mama.
TH102680A (th) การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
MY128724A (en) Liver selective theraphy.
DE60209757D1 (de) Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n-dimethylglycin
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
ATE339209T1 (de) Kombinationstherapie mit gemzitabin und zd6126